Analyst Reco. Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
14.92 ^USD	+12.94%		-0.27%	+2.19%

24/04	Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	MT
24/04	Transcript : Day One Biopharmaceuticals, Inc. - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	24/04	MT
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating	22/04	MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating	28/02	MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating	27/02	MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating	27/02	MT
Wedbush Lowers Day One Biopharmaceuticals' Price Target to $35 From $39, Keeps Outperform Rating	07/11	MT
Wedbush Lifts Day One Biopharmaceuticals' PT to $39 From $38 After Tovorafenib Receives Priority Review, Maintains Outperform Rating	31/23/31	MT
Goldman Sachs Lowers Price Target on Day One Biopharmaceuticals to $54 From $63, Maintains Buy Rating	08/23/08	MT
HC Wainwright Raises Price Target on Day One Biopharmaceuticals to $50 From $45, Keeps Buy Rating	05/23/05	MT
Needham Cuts Price Target on Day One Biopharmaceuticals to $40 From $44, Maintains Buy Rating	08/23/08	MT
BofA Securities Downgrades Day One Biopharmaceuticals to Underperform From Buy, Adjusts Price Target to $9 From $34	25/23/25	MT
Needham Adjusts Price Target on Day One Biopharmaceuticals to $44 From $48, Keeps Buy Rating	05/23/05	MT
Capital One Starts Day One Biopharmaceuticals at Overweight With $40 Price Target	08/23/08	MT
Oppenheimer Initiates Coverage on Day One Biopharmaceuticals With Perform Rating	03/23/03	MT
Piper Sandler Adjusts Day One Biopharmaceuticals' Price Target to $45 From $40, Keeps Overweight Rating	09/23/09	MT
HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $45 From $35, Maintains Buy Rating	09/23/09	MT
Goldman Sachs Adjusts Price Target on Day One Biopharmaceuticals to $62 From $45, Maintains Buy Rating	09/23/09	MT
Wedbush Raises Day One Biopharmaceuticals' PT to $38 From $35 After Positive Topline Results From FIREFLY-1 Study, Keeps Outperform Rating	09/23/09	MT
HC Wainwright Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $35 Price Target	15/22/15	MT
Needham Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $40 Price Target	14/22/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Analyst Reco.

Filters